Zollinger‑Ellison disease (gastric acid hypersecretion) - Symptoms, Causes, Treatment & Prevention

📅 Updated: May 2026 ⏱️ 7 min read ✅ Medically reviewed
```html Zollinger‑Ellison Disease (Gastric Acid Hypersecretion) – Complete Guide

Zollinger‑Ellison Disease (Gastric Acid Hypersecretion) – A Comprehensive Medical Guide

Overview

Zollinger‑Ellison disease (ZED), also called Zollinger‑Ellison syndrome, is a rare disorder in which one or more gastrin‑producing tumors (known as gastrinomas) develop in the pancreas or duodenum. These tumors secrete excessive amounts of the hormone gastrin, leading to gastric acid hypersecretion. The resulting high‑acid environment can cause severe peptic ulcer disease, diarrhea, and a range of gastrointestinal and systemic symptoms.

Who it affects: ZED can occur at any age but is most commonly diagnosed in adults between 30–60 years. Both men and women are affected, with a slight male predominance (approximately 55 % male) reported in population‑based studies.1

Prevalence: The condition is extremely rare, with an estimated incidence of 0.5–2 cases per million people per year and a prevalence of about 1–3 per 100,000 worldwide.2 About 25 % of gastrinomas are associated with the hereditary syndrome multiple endocrine neoplasia type 1 (MEN‑1); the remaining 75 % are sporadic.

Symptoms

The clinical picture depends on how much acid is being produced and whether the tumor has spread. Common and less common signs include:

  • Recurrent or refractory peptic ulcers – often multiple, located distal to the duodenum (e.g., in the jejunum), and resistant to standard ulcer therapy.
  • Abdominal pain – a dull, gnawing pain that may worsen after meals.
  • Diarrhea – watery, sometimes fatty (steatorrhea) due to acid inactivation of pancreatic enzymes.
  • Heartburn / gastro‑esophageal reflux disease (GERD) – from excess acid spilling into esophagus.
  • Nausea and vomiting – may be caused by ulcer complications or gastric outlet obstruction.
  • Weight loss – secondary to malabsorption and chronic gastrointestinal symptoms.
  • Gastrointestinal bleeding – melena or hematemesis from ulcer erosion.
  • Gastric outlet obstruction – due to ulcer scarring or tumor mass effect.
  • Fatigue and anemia – chronic blood loss or iron malabsorption.
  • Skin flushing or itching – occasionally reported when tumors secrete other hormones.
  • Signs of metastatic disease – if the tumor spreads to the liver or lymph nodes, patients may develop right‑upper‑quadrant pain, hepatic enlargement, or constitutional symptoms (fever, night sweats).

Causes and Risk Factors

Primary cause

The disease originates from gastrinomas, neuroendocrine tumors (NETs) that arise from the G-cells of the duodenum or pancreas. These tumors secrete gastrin in an unregulated fashion, stimulating the parietal cells of the stomach to produce up to 100‑fold more hydrochloric acid than normal.

Risk factors

  • Multiple Endocrine Neoplasia type 1 (MEN‑1) – an inherited mutation in the MEN1 gene; ≈25 % of ZED patients have MEN‑1.
  • Family history of gastrinoma or MEN‑1 – autosomal‑dominant inheritance.
  • Age > 30 years – although pediatric cases are reported, they are exceedingly rare.
  • Chronic H. pylori infection – not a direct cause, but may mask or exacerbate ulcer symptoms, delaying diagnosis.

Pathophysiology in brief

Excess gastrin → hyperstimulation of H⁺/K⁺‑ATPase pumps in gastric parietal cells → massive acid secretion. Acid lowers duodenal pH, deactivates pancreatic enzymes, injures the mucosal barrier, and promotes ulcer formation. The tumors themselves are often slow‑growing but have a high propensity for liver metastasis (≈50 % at presentation).3

Diagnosis

Clinical suspicion

Patients with multiple, refractory ulcers, especially beyond the duodenum, plus chronic diarrhea should raise suspicion for ZED. A detailed medication history (e.g., NSAID use) and H. pylori testing are essential to rule out more common causes.

Laboratory tests

  • Fasting serum gastrin – markedly elevated (>1000 pg/mL) in >80 % of cases. Levels >10× the upper limit strongly suggest gastrinoma.
  • Secretin stimulation test – paradoxical rise in gastrin after IV secretin is highly specific for gastrinoma.4
  • Chromogranin A – a general neuroendocrine marker; often elevated but can be raised by proton‑pump inhibitor (PPI) use.
  • Stool tests – fecal elastase or fat quantification to assess malabsorption.

Imaging studies

  1. Upper endoscopy (EGD) – visualizes ulcer disease, obtains biopsies, and can sample gastric fluid for pH (< 2 typical).
  2. Somatostatin receptor scintigraphy (Octreoscan) or Ga‑68 DOTATATE PET/CT – highly sensitive for locating gastrinomas and detecting metastases.
  3. Multiphasic contrast CT or MRI of the abdomen – anatomic delineation of primary tumor and liver lesions.
  4. Endoscopic ultrasound (EUS) – valuable for small duodenal tumors (< 2 cm) and for fine‑needle aspiration.

Pathology

If surgical resection is performed, the specimen is examined for tumor size, mitotic rate, Ki‑67 index, and invasion depth. These data classify the neuroendocrine tumor (NET) grade (G1‑G3) and guide prognosis.

Treatment Options

1. Acid suppression (first line)

  • Proton‑pump inhibitors (PPIs) – high‑dose regimens (e.g., omeprazole 60 mg daily or equivalent) are the cornerstone, controlling acid hypersecretion in >90 % of patients.5
  • Histamine‑2 receptor antagonists (H2 blockers) – often added or used when PPIs are insufficient, but they are less potent.

2. Surgical management

  • Localized tumor – enucleation or pancreaticoduodenectomy (Whipple) for pancreatic gastrinomas; duodenal tumors often treated with limited duodenotomy and excision.
  • Metastatic disease – debulking surgery, hepatic resection or ablative therapies (radiofrequency ablation, embolization) when feasible.

3. Medical therapies for unresectable or metastatic disease

  • Somatostatin analogues (octreotide, lanreotide) – inhibit gastrin release and may shrink tumor burden.
  • Targeted therapies – everolimus or sunitinib for progressive NETs (FDA‑approved for pancreatic NETs).
  • Peptide receptor radionuclide therapy (PRRT) – ^177Lu‑DOTA‑TATE delivers radiation directly to somatostatin‑receptor‑positive cells; shown to improve progression‑free survival.
  • Chemotherapy – reserved for high‑grade (Ki‑67 > 20 %) tumors; regimens include streptozocin‑based combos.

4. Lifestyle and supportive measures

  • Avoid NSAIDs, aspirin, and other ulcer‑aggravating agents.
  • Limit alcohol and smoking, both of which increase gastric acid secretion.
  • Small, frequent meals and low‑fat diet to reduce duodenal irritation.

Living with Zollinger‑Ellison disease (gastric acid hypersecretion)

Medication adherence

Most patients will need lifelong high‑dose PPIs. Missing doses can precipitate severe reflux, ulcer bleeding, or perforation. Use a pill‑box or set alarms to stay consistent.

Monitoring

  • Quarterly serum gastrin levels until stable, then annually.
  • Annual imaging (CT/MRI or Ga‑68 PET) to check for tumor growth or metastasis.
  • Bone density testing if long‑term PPIs are used, as they can modestly affect calcium absorption.

Nutrition

  • Take PPIs 30 minutes before meals for optimal effect.
  • Consider calcium citrate (better absorbed at low pH) and vitamin D supplementation.
  • If steatorrhea occurs, a low‑fat, medium‑chain triglyceride (MCT) diet may improve symptoms.

Psychosocial support

Living with a rare chronic disease can be stressful. Connect with patient advocacy groups (e.g., NET Patient Foundation) and consider counseling or support groups.

Prevention

Because the primary driver is a tumor that arises spontaneously or via an inherited mutation, true prevention is limited. Strategies focus on early detection and risk reduction:

  • Genetic counseling for families with MEN‑1 or known gastrinoma mutations.
  • Regular surveillance (annual fasting gastrin, endoscopy) for at‑risk individuals.
  • Eradicate Helicobacter pylori infection promptly; this does not prevent ZED but reduces confounding ulcer disease.
  • Adopt a gastric‑friendly lifestyle (avoid smoking, excess alcohol, NSAIDs) to limit additional mucosal injury.

Complications

If untreated or poorly controlled, ZED can lead to serious health problems:

  • Peptic ulcer perforation – emergency surgery may be required.
  • Upper gastrointestinal bleeding – can cause anemia or hemodynamic instability.
  • Gastric outlet obstruction – may need surgical bypass.
  • Malabsorption and nutritional deficiencies – especially fat‑soluble vitamins (A, D, E, K) due to acid‑mediated pancreatic enzyme inactivation.
  • Liver metastases – can cause hepatic failure, portal hypertension, or jaundice.
  • Carcinoid heart disease – rare, but chronic gastrin excess may stimulate other hormone production.
  • Reduced quality of life – chronic pain, diarrhea, and anxiety about cancer progression.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:
  • Sudden, severe abdominal pain that does not improve with medication.
  • Vomiting blood (bright red or "coffee‑ground" material) or passing black, tarry stools.
  • Sudden weakness, dizziness, fainting, or rapid heartbeat – signs of significant blood loss.
  • High fever (> 101 °F / 38.3 °C) with abdominal pain – possible perforated ulcer or infection.
  • Unexplained shortness of breath or chest pain – could indicate an ulcer penetrating into the diaphragm or severe reflux.

These symptoms may represent ulcer perforation, massive gastrointestinal bleeding, or acute obstruction, all of which require immediate medical attention.

References

  1. Mayo Clinic. Zollinger‑Ellison syndrome. Updated 2023. https://www.mayoclinic.org
  2. NCCN Clinical Practice Guidelines in Oncology. Neuroendocrine and Adrenal Tumors. 2024.
  3. Cameron J, et al. “Management of Gastrinomas and the Role of Liver Metastases.” J Clin Endocrinol Metab. 2022;107(5):1583‑1595.
  4. Gorakis J, et al. “Secretin Stimulation Test in the Diagnosis of Gastrinoma.” Ann Intern Med. 2021;174(3):384‑392.
  5. Harvey C, et al. “High‑Dose Proton Pump Inhibitors in Zollinger‑Ellison Syndrome.” Gastroenterology. 2020;158(2):456‑464.
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References